美国

我们是谁

  • 10 月 31, 2023
    表达高亲和性 KRASG12V 突变特异性 T 细胞受体的自体 CD8+ 和 CD4+ 转基因 T 细胞（FH-A11KRASG12V-TCR）用于治疗 KRAS G12V 突变的转移性胰腺癌、结直肠癌和非小细胞肺癌患者
  • 10 月 17, 2023
    Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
  • 8 月 31, 2023
    A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
  • 8 月 31, 2023
    Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer
  • 7 月 24, 2023
    Fc-Engineered Anti-CTLA-4 Monoclonal Antibody Botensilimab in Advanced Cancer
  • 4 月 12, 2023
    Evaluation for NCI Surgery Branch Immunotherapy Clinical Research Protocols
  • 2 月 7, 2023
    A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer Without Liver Metastases
  • 2 月 7, 2023
    Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy
  • 1 月 19, 2023
    Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer
  • 12 月 8, 2022
    FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer